ロード中...
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Background To determine the recommended phase II dose (RP2D) and assess the safety, pharmacokinetics (PKs) and pharmacodynamics of RO4929097in combination with temsirolimus. Methods Escalating doses of RO4929097 and temsirolimus were administered at three dose levels. Patients received once daily or...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2013
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3771370/ https://ncbi.nlm.nih.gov/pubmed/23860641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0001-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|